Page last updated: 2024-08-23

mefloquine and Stomach Neoplasms

mefloquine has been researched along with Stomach Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, S; Di, M; Liu, Y; Xue, R; Zhao, J	1

Other Studies

1 other study(ies) available for mefloquine and Stomach Neoplasms

Article	Year
Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. Biochemical and biophysical research communications, 2016, Feb-05, Volume: 470, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mefloquine; Mice; Mice, SCID; Molecular Targeted Therapy; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Treatment Outcome	2016

Article

Year

Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.

Biochemical and biophysical research communications, 2016, Feb-05, Volume: 470, Issue:2

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mefloquine; Mice; Mice, SCID; Molecular Targeted Therapy; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Treatment Outcome

2016